Eric Lefkofsky is a disruptor. He is perhaps best known for disrupting the way consumers have access to discounts from vendors who want them to purchase their goods, services or experience through his massively successful venture Groupon and more information click here.
Lefkofsky is now seeking to become a revolutionary disruptor once again by disrupting the way cancer is treated. Anyone who is familiar with Lefkofsky or his innovative business style knows that he is driven to be a problem solver, to innovate when it seems there is no space for innovation and to disrupt the status quo with cutting edge ideas and technology. When his wife was unexpectedly diagnosed with breast cancer he was at a loss for why with all the data being collected from cancer patients, there was still no synchronized and streamlined system to access that data in a useful way and learn more about Eric.
It was this inquiry that gave birth to Tempus. Tempus is seeking to approach human genomic data in a new way that will allow for data-driven cancer treatment and care. The company’s goal is to compile massive amounts of molecular and clinical data to build the largest library of data in the world and to utilize an operating platform that will bring that data to the fingertips of cancer researchers and physicians everywhere and Eric’s lacrosse camp.
Tempus was featured recently in Tech News Spy in an article focusing on how Tempus and Lefkofsky were pushing data-enabled precision medicine to the next level through tech like the Tempus platform. While Tempus isn’t the only company pushing for this data to be made usable, it is the first to build a platform that has successfully collected patient data from physician’s notes. Physicians notes contain huge volumes of data about individual patients, but until now haven’t been curated into a usable platform. Tempus’s operating system reads those notes similar to how a human would read them and indexes them so that they are readily available through the system when needed. It is the hope that this system will be paired with molecular data from human genome studies to be available worldwide to cancer researchers and physicians.